Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) will announce its earnings results after the market closes on Monday, August 8th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Y-mAbs Therapeutics has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.07. Y-mAbs Therapeutics had a negative net margin of 291.89% and a negative return on equity of 59.67%. The firm had revenue of $10.49 million for the quarter, compared to the consensus estimate of $11.10 million. During the same period last year, the firm earned $0.75 earnings per share. The company’s quarterly revenue was up 94.8% on a year-over-year basis. On average, analysts expect Y-mAbs Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Y-mAbs Therapeutics Stock Up 2.8 %
NASDAQ:YMAB opened at $18.96 on Friday. Y-mAbs Therapeutics has a 52 week low of $6.50 and a 52 week high of $39.82. The firm has a 50 day moving average of $15.27 and a 200 day moving average of $11.90. The stock has a market capitalization of $828.82 million, a price-to-earnings ratio of -7.07 and a beta of 1.15.
Institutional Trading of Y-mAbs Therapeutics
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on YMAB shares. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, April 29th. Wedbush reduced their target price on shares of Y-mAbs Therapeutics from $28.00 to $21.00 and set an “outperform” rating for the company in a report on Tuesday, May 10th. Finally, BMO Capital Markets began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, June 23rd. They set an “outperform” rating and a $27.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.83.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
- Get a free copy of the StockNews.com research report on Y-mAbs Therapeutics (YMAB)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.